Research programme: gliadin protein therapeutics - Diamyd Medical

Drug Profile

Research programme: gliadin protein therapeutics - Diamyd Medical

Latest Information Update: 12 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Diamyd Medical AB
  • Class Proteins
  • Mechanism of Action Gliadin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Coeliac disease; Type 1 diabetes mellitus

Most Recent Events

  • 31 Aug 2015 Diamyd Medical licenses a drug candidate from undisclosed inventors, for the treatment of type I diabetes and coeliac disease
  • 31 Aug 2015 Diamyd Medical files for patent protection for methods and formulations of gliadin, in combination with other compounds
  • 31 Aug 2015 Preclinical trials in Coeliac disease in Sweden (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top